Toray Industries, Inc.

Sayoko Kanie

Ryoji Hayashi

Koji Kawai

Masaki Arai

Ko Hasebe

Morihiro Fujimura

Tsukasa Kikuchi

Satoshi Kurosawa

Seiichiro Ozono

Atsushi Otsuka

Yohei Noro

The benzylamine derivative represented by the formula below and a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical containing the derivative or the pharmaceutically acceptable acid addition salt thereof, and a therapeutic or prophylactic agent for pollakiuria or urinary incontinence containing the derivative or the pharmaceutically acceptable acid addition salt thereof are provided. The benzylamine derivative of the present invention and the pharmaceutically acceptable acid addition salt thereof have less possibility of occurrence of side effects than known compounds, and show a better therapeutic effect against pollakiuria or urinary incontinence, so that they can be used as excellent therapeutic or prophylactic agents for pollakiuria or urinary incontinence. 

Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes

A method for therapy of diarrhea-predominant irritable bowel disorders comprising as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic group or a pharmaceutically acceptable acid addition salt thereof is disclosed. The method for therapy of diarrhea-predominant irritable bowel disorders comprises as an effective ingredient a morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, having a specific structure, such as N-(17-cyclopeopylmethyl-4,5&#x3b1;-epoxy-3,14-dihydroxy-morphinan-6&#x3b2;-yl)-3,4,5,6-tetrahydrophthalimide tartaric acid salt (Compound 10). 

Method for therapy of diarrhea-predominant irritable bowel disorders

Growing community of inventors

Kanagawa, Japan

Sayoko Kanie